Faculty Bibliography

Background: Unfavorable outcomes for stepwise linear ablation of non-paroxysmal atrial fbrillation (NPAF) in clinical trials may be attributable to pro-arrhythmic effects of incomplete ablation lines. It is unknown if recurrent arrhythmia following stepwise linear ablation is more likely to be successfully ablated compared to recurrent arrhythmia following a more limited initial procedure The optimal ablation strategy for catheter ablation of NPAF using a contact-force sensing (CFS) radiofrequency ablation (RFA) catheter remains unclear. Objective: To compare 2-procedure outcomes of stepwise linear RFA to left atrial posterior wall isolation in patients undergoing NPAF ablation using a CFS RFA catheter. Methods: We compared clinical outcomes of two cohorts of 100 consecutive NPAF patients undergoing frst-time RFA using a CFS RFA catheter. Group 1: stepwise linear ablation (July 2014-July 2015); Group 2: left atrial posterior wall isolation (October 2015-June 2016). Arrhythmia recurrence was assessed using 2-week event monitors at 3-month intervals following ablation procedures. Results: Baseline characteristics of the two groups were similar. Mean follow-up time was 656 +/- 361 days for Group 1 and 436 +/- 228 days for Group 2. At 24-month follow up, Kaplan-Meier estimated single procedure arrhythmia free survival was signifcantly greater in Group 2 compared to Group 1 (76% vs 59%, respectively; p = 0.01), primarily driven by a higher rate of recurrence of atrial tachycardia (12% vs 35%, respectively; p < 0.001). Among patients with recurrent arrhythmia after a single procedure, Group 2 patients were less likely to require repeat ablation compared to Group 1 (6/24 vs 34/41, respectively; p < 0.001) and less likely to recur after repeat ablation (1/6 vs 13/34, respectively; p = 0.001). Conclusion: Compared to stepwise linear ablation, LA posterior wall isolation for catheter ablation of NPAF resulted in a lower incidence of recurrent arrhythmia at 2 years, a lower likelihood of requiring repeat ablation amongst patients with recurrence, and a lower likelihood of recurrence following a second ablation

Background: Unfavorable outcomes observed with stepwise linear ablation of non-paroxysmal AF (NPAF) in large clinical trials utilizing ablation catheters without contact-force sensing (CFS) may be attributable to pro-arrhythmic effects of incomplete ablation lines. The optimal ablation strategy for catheter ablation of NPAF using a contact force sensing radiofrequency (RF) ablation catheter remains unclear. Objective: To compare catheter ablation outcomes of stepwise linear ablation to left atrial (LA) posterior wall isolation in patients undergoing NPAF ablation using a CFS RF ablation catheter. Methods: We performed pulmonary vein antral isolation (PVAI) followed by isolation of the LA posterior wall in 80 consecutive patients undergoing first-time NPAF ablation between November 2015 and March 2016 (Group 1) and compared clinical outcomes to those of 112 consecutive patients who underwent PVAI followed by step-wise linear ablation for NPAF between May 2014 and November 2015 (Group 2). All ablation procedures were performed using the Carto 3 mapping system and SmartTouch RF ablation catheter (Biosense Webster, Inc.). Arrhythmia recurrence was assessed using 2-week event monitors at 3-month intervals. Arrhythmia-free survival at 12 months was estimated using the Kaplan-Meier method. Results: Baseline characteristics of Group 1 and Group 2 were similar. At 12 months follow-up, arrhythmia-free survival was significantly greater in Group 1 patients compared with Group 2 (81.9% vs. 67.5%, respectively; p=0.0318). There was no significant difference in survival free from AF between group 1 and group 2 (89% vs. 84.1%, respectively; p=0.3431), however group 1 patients developed significantly fewer post-ablation atrial tachycardias (AT) than group 2 patients (8.1% vs 30.1%, respectively; p<0.001). Conclusion: Among patients undergoing NPAF ablation using a contact force sensing RF ablation catheter, LA posterior wall isolation resulted in fewer recurrent atrial arrhythmias than a stepwise linear approach. The reduction in recurrent atrial arrhythmias is driven primarily by a reduction in recurrent AT

Bleeding and thrombotic complications continue to plague continuous-flow left ventricular assist device (CF-LVAD) therapy in patients with end-stage heart failure. Warfarin genotyping information can be incorporated into decision making for initial dosing as recommended by the Food and Drug Administration; however, clinical utility of this data in the CF-LVAD population has not been well studied. Genotypes testing for CYP2C9 and VCORC1 polymorphisms were determined in 90 CF-LVAD patients. Outcomes studied were the association of CYP2C9 (*1, *2, or *3) and VKORC1 (-1639 G>A) gene variants with time-to-target international normalized ratio (INR), total warfarin dose, maintenance warfarin dose. Continuous-flow left ventricular assist device patients carrying a rare variant in the VKORC1 gene had a significantly lower cumulative warfarin dose until target INR achieved (18.9 vs. 35.0 mg, p = 0.002), days spent until INR target achieved (4.9 vs. 7.0 days, p = 0.021), and discharge warfarin dose (3.2 vs. 5.6 mg, p = 0.001) compared with patients with wild-type genotype. Genotype-guided warfarin dosing may lead to safer anticoagulation and potentially improve outcomes in CF-LVAD patients.

Introduction: Large clinical trials have recently demonstrated stepwise linear ablation for non-paroxysmal atrial fibrillation (NPAF) to be inferior to pulmonary vein isolation alone. It is unknown whether the unfavorable outcomes observed in these trials can be attributed to the pro-arrhythmic effects of incomplete ablation lines. We hypothesized that improved lesion quality related to use of contact-force sensing (CFS) ablation catheters would improve procedural outcomes. Methods: We prospectively analyzed procedural outcomes of 74 consecutive patients with NPAF undergoing first-time radiofrequency catheter ablation with a CFS catheter (Smart Touch, Biosense Webster) using a step-wise approach (Group 1). The clinical outcomes of these patients were compared with 74 consecutive patients with NPAF who underwent catheter ablation between September 2013 and June 2014 with a non-contact force sense radiofrequency ablation catheter (Group 2) at a single tertiary care medical center. Arrhythmia recurrence was assessed using 2-week event monitors at 3-month intervals following index ablation. Results: Baseline characteristics of Group 1 and Group 2 were similar, although in Group 1 there was a greater prevalence of patients with persistent NPAF lasting for 6-months or longer prior to initial ablation (43% vs 21%, p=0.071). The recurrence rate at 1 year as estimated by the Kaplan-Meier method was not significantly different between Group 1 and Group 2 (25.7% vs 29.7%, p=0.582). The presenting recurrent arrhythmia was most frequently atrial tachycardia (AT) in both groups (Group 1: n=19, AT 68.4% and AF 31.6% vs Group 2: n=22, AT 59.1% and AF 40.9%). A similar proportion of patients in both groups underwent repeat ablation (Group 1: 17.6% vs Group 2: 13.5%, p=0.496). Conclusions: Utilization of a CFS ablation catheter was not associated with improved clinical outcomes for stepwise catheter ablation for NPAF. The optimal strategy for NPAF ablation using a contact-force sensing catheter remains undefined

As more women with repaired congenital heart disease survive to their reproductive years and many other women are delaying pregnancy until later in life, a rising concern is the risk of cardiac arrhythmias during pregnancy. Naturally occurring cardiovascular changes during pregnancy increase the likelihood that a recurrence of a previously experienced cardiac arrhythmia or a de novo arrhythmia will occur. Arrhythmias should be thoroughly investigated to determine if there is a reversible etiology, and risks/benefits of treatment options should be fully explored. We discuss the approach to working up and treating various arrhythmias during pregnancy with attention to fetal and maternal risks as well as treatment of fetal arrhythmias. Acute management in stable patients includes close monitoring and intravenous pharmacologic therapy, while DC cardioversion should be used to terminate arrhythmias in hemodynamically unstable patients. Long-term management may require continued oral antiarrhythmic therapy, with particular attention to fetal safety, to prevent complications associated with arrhythmias.

BACKGROUND AND PURPOSE/OBJECTIVE:We assess whether the electrocardiographic (ECG) pattern of ST depression in >7 body surface leads combined with ST elevation in aVR and V1 is predictive of left main coronary artery (LMCA) stenosis or left main equivalent (LMEQ) disease. METHODS:We collected 133 patients showing this particular ECG pattern. Patients with left bundle branch block, ventricular rhythm or ventricular paced rhythm were excluded. RESULTS:Only 28% of the patients had non-ST elevation acute coronary syndrome (NSTE-ACS). ECGs were classified as chronic, dynamic or no prior in 28%, 48% and 24%, respectively. A total of 57 patients (44%) underwent coronary angiography (CA). No significant coronary artery disease was found in 26%. LMCA/LMEQ disease was found in only 23% of these patients. The positive predictive value of the ECG pattern was not improved after exclusion of patients with intraventricular conduction abnormalities and left ventricular hypertrophy or in patients with dynamic ECG changes. CONCLUSIONS:This ECG pattern is not always caused by LMCA/LMEQ disease; therefore, the term "suspect circumferential subendocardial ischemia" may be preferred. Other medical conditions may also be associated with a similar ECG pattern.